Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Prostatic Neoplasms 2Neuroblastoma 2Breast Neoplasms 2Waldenstrom Macroglobulinemia 1Unspecified Adult Solid Tumor, Protocol Specific 1Small Cell Lung Carcinoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lung Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1Gliosarcoma 1Glioblastoma 1Carcinoma, Ovarian Epithelial 1Camurati-Engelmann Syndrome 1Burkitt Lymphoma 1Brain Neoplasms 1

Interventions

Fenretinide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Camurati-Engelmann Syndrome × Fenretinide × Clear all
NCT00001378 2008-03-04

A Pilot Trial of Tamoxifen and 4-HPR (4-N-Hydroxyphenyl Retinamide) in Persons at High Risk for Developing Breast Cancer

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
75 enrolled
Breast

Breast Neoplasms, Camurati-Engelmann Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡